In an unusual court case, two people are suing Amgen for the right to use an experimental Parkinson's drug that the biotech concluded could be dangerous to their health. The case revolves around GDNF, which Amgen shelved after examining trial data last year. Amgen's attorney told a federal judge that the drug represented an unreasonable risk. But two Parkinson's patients who took the drug insist that it could be their only hope for improving their condition.
- read the story from the Los Angeles Times for more